| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.22053 |
| P698 | PubMed publication ID | 20517932 |
| P2093 | author name string | Justin C McArthur | |
| Avi Nath | |||
| Ned Sacktor | |||
| Joseph Steiner | |||
| P433 | issue | 6 | |
| P304 | page(s) | 699-714 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap | |
| P478 | volume | 67 |
| Q37043212 | "My body's a 50 year-old but my brain is definitely an 85 year-old": exploring the experiences of men ageing with HIV-associated neurocognitive challenges |
| Q49961078 | 7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests. |
| Q47989010 | A Gap in Time: Extending our Knowledge of Temporal Processing Deficits in the HIV-1 Transgenic Rat. |
| Q99617860 | A Novel Concept is Needed for Combating Alzheimer's Disease and NeuroHIV |
| Q64115953 | A Novel Role of Prolidase in Cocaine-Mediated Breach in the Barrier of Brain Microvascular Endothelial Cells |
| Q36283322 | A Novel Role of Proline Oxidase in HIV-1 Envelope Glycoprotein-induced Neuronal Autophagy |
| Q59353529 | A Quantitative Approach to SIV Functional Latency in Brain Macrophages |
| Q37541514 | A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV |
| Q36120146 | A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers |
| Q40463006 | A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. |
| Q36345352 | A family history of substance dependence obscures the group differences in brain function associated with HIV-1 and ART. |
| Q37463446 | A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects |
| Q34482480 | A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia |
| Q30548228 | A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder |
| Q98163711 | A pivotal role for Interferon-α receptor-1 in neuronal injury induced by HIV-1 |
| Q36989920 | A plasma microRNA signature of acute lentiviral infection: biomarkers of central nervous system disease |
| Q54975048 | A study of neuropsychological profile of human immunodeficiency virus-positive children and adolescents on antiretroviral therapy. |
| Q35106267 | Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people |
| Q30362822 | Adaptive working memory training improved brain function in human immunodeficiency virus-seropositive patients. |
| Q42069973 | Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons |
| Q34692081 | Adjuvant therapies for HIV-associated neurocognitive disorders |
| Q38490362 | Ageing with HIV: a multidisciplinary review. |
| Q59357369 | Aging and Apolipoprotein E in HIV Infection |
| Q38368637 | Aging, Health, and Quality of Life for Older People Living With HIV in Sub-Saharan Africa: A Review and Proposed Conceptual Framework |
| Q36169735 | Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders |
| Q37432530 | Altered subcellular localization of the NeuN/Rbfox3 RNA splicing factor in HIV-associated neurocognitive disorders (HAND). |
| Q26829172 | An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research |
| Q42137720 | Anti-inflammatory Function of Phyllostachys Edulis Extract in the Hippocampus of HIV-1 Transgenic Rats |
| Q37024994 | Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. |
| Q36439056 | Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage |
| Q37467991 | Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection |
| Q36853897 | Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program |
| Q36433552 | Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women |
| Q35624697 | Autophagy in dementias |
| Q36798111 | Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus |
| Q27011721 | CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens |
| Q92872266 | CXCL12-induced rescue of cortical dendritic spines and cognitive flexibility |
| Q42206762 | Cannabinoid receptor-2 and HIV-associated neurocognitive disorders. |
| Q34377373 | Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway |
| Q36670527 | Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders |
| Q36883462 | Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes |
| Q35878624 | Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders |
| Q64910543 | Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy. |
| Q41528498 | Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients |
| Q33863368 | Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment |
| Q40104529 | Changing clinical phenotypes of HIV-associated neurocognitive disorders |
| Q36655192 | Characterization of neuropathology in the HIV-1 transgenic rat at different ages. |
| Q33573879 | Characterization of platelet-monocyte complexes in HIV-1-infected individuals: possible role in HIV-associated neuroinflammation |
| Q36985189 | Cocaine Enhances HIV-1 Transcription in Macrophages by Inducing p38 MAPK Phosphorylation. |
| Q35057500 | Cognitive impairment in patients with AIDS - prevalence and severity |
| Q35037015 | Controversies in HIV-associated neurocognitive disorders |
| Q27013928 | Cortical consequences of HIV-1 Tat exposure in rats are enhanced by chronic cocaine |
| Q35214668 | Cortical neurons are a prominent source of the proinflammatory cytokine osteopontin in HIV-associated neurocognitive disorders |
| Q47612809 | Cross-sectional and longitudinal small animal PET shows pre and post-synaptic striatal dopaminergic deficits in an animal model of HIV. |
| Q36932005 | Current understanding of HIV-associated neurocognitive disorders pathogenesis |
| Q83974381 | Cytokine levels in CSF and neuropsychological performance in HIV patients |
| Q46272109 | Dementia Prevalence in a Rural Region of South Africa: A Cross-Sectional Community Study. |
| Q36406259 | Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz |
| Q35440924 | Depression in HIV infected patients: a review |
| Q90340525 | Determining the Neurocognitive Status and the Functional Ability of Patients to Screen for HIV-Associated Neurocognitive Disorder (HAND) |
| Q35522971 | Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection |
| Q49711913 | Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India |
| Q40668682 | Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. |
| Q61443126 | Disruption of Timing: NeuroHIV Progression in the Post-cART Era |
| Q36993831 | Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders |
| Q99713341 | Effect of Opioid Use on Immune Activation and HIV Persistence on ART |
| Q40052643 | Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro |
| Q34383417 | Effects of HIV-1 Tat on enteric neuropathogenesis. |
| Q35123216 | Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior |
| Q34080255 | Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study |
| Q35115524 | Effects of information processing speed on learning, memory, and executive functioning in people living with HIV/AIDS. |
| Q28660034 | Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism |
| Q40046051 | Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy |
| Q34057907 | Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis |
| Q24612874 | Eradication of HIV from the brain: reasons for pause |
| Q37294737 | Evaluating sleep and cognition in HIV |
| Q92206566 | Evaluating the Feasibility and Impact of a Yoga Intervention on Cognition, Physical Function, Physical Activity, and Affective Outcomes in People Living With HIV: Protocol for a Randomized Pilot Trial |
| Q33690042 | Evidence of the innate antiviral and neuroprotective properties of progranulin |
| Q40113815 | Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders. |
| Q50421213 | Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration |
| Q34024194 | Exploring Substance Use and HIV Treatment Factors Associated with Neurocognitive Impairment among People Living with HIV/AIDS. |
| Q39527006 | Extracting patterns of morphometry distinguishing HIV associated neurodegeneration from mild cognitive impairment via group cardinality constrained classification |
| Q36872842 | Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning |
| Q33721196 | Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage |
| Q38245110 | Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors |
| Q58750745 | HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links? |
| Q40404098 | HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. |
| Q38824376 | HIV and viral protein effects on the blood brain barrier |
| Q89775600 | HIV influences microtubule associated protein-2: Potential marker of HIV-associated neurocognitive disorders |
| Q42011853 | HIV-1 Gp120 clade B/C induces a GRP78 driven cytoprotective mechanism in astrocytoma. |
| Q59357751 | HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy |
| Q37282230 | HIV-1 Tat Inhibits Autotaxin Lysophospholipase D Activity and Modulates Oligodendrocyte Differentiation |
| Q45033937 | HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. |
| Q36944251 | HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes |
| Q36634476 | HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions |
| Q36185385 | HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND. |
| Q36407266 | HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase. |
| Q26766448 | HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment |
| Q33939729 | HIV-associated neurocognitive disorder. |
| Q27015965 | HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities |
| Q37971469 | HIV-associated neurological disorders: a guide to pharmacotherapy |
| Q38433342 | High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection |
| Q64082246 | High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: A cross-sectional study |
| Q47734973 | Hippocampal GABAergic Inhibitory Interneurons |
| Q42700219 | Human Endogenous Retrovirus-K and TDP-43 Expression Bridges ALS and HIV Neuropathology |
| Q50200827 | Human Immunodeficiency Virus in the Brain-Culprit or Facilitator? |
| Q33837077 | Human endogenous retrovirus-K(II) envelope induction protects neurons during HIV/AIDS. |
| Q36330062 | Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication |
| Q38645990 | Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications |
| Q35178171 | Impact of cerebrovascular disease on cognitive function in HIV-infected patients |
| Q26779435 | Impact of cocaine abuse on HIV pathogenesis |
| Q34718216 | Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment |
| Q33611467 | Impairments of Motor Function While Multitasking in HIV. |
| Q37351271 | Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors |
| Q37659348 | Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. |
| Q37181324 | Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection |
| Q35996364 | Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue. |
| Q35876821 | Induction of Interleukin-1β by Human Immunodeficiency Virus-1 Viral Proteins Leads to Increased Levels of Neuronal Ferritin Heavy Chain, Synaptic Injury, and Deficits in Flexible Attention. |
| Q34756398 | Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study |
| Q35669007 | Insights into end-organ injury in HIV infection: dynamics of monocyte trafficking to the brain in SIV encephalitis |
| Q40508985 | Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. |
| Q35530481 | Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals |
| Q27339182 | Interaction of paroxetine with mitochondrial proteins mediates neuroprotection |
| Q35757268 | Intra-ventral tegmental area HIV-1 Tat1-86 attenuates nicotine-mediated locomotor sensitization and alters mesocorticolimbic ERK and CREB signaling in rats |
| Q34377523 | Involvement of IRS-1 interaction with ADAM10 in the regulation of neurite extension |
| Q53691998 | Is Tobacco Use Associated with Neurocognitive Dysfunction in Individuals with HIV? |
| Q36084239 | Isobaric tagging-based quantification by mass spectrometry of differentially regulated proteins in synaptosomes of HIV/gp120 transgenic mice: implications for HIV-associated neurodegeneration. |
| Q36070781 | Lack of neuroinflammation in the HIV-1 transgenic rat: an [(18)F]-DPA714 PET imaging study |
| Q35054688 | Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS. |
| Q45325864 | Lifetime marijuana and alcohol use, and cognitive dysfunction in people with human immunodeficiency virus infection. |
| Q37646749 | Ligand-gated purinergic receptors regulate HIV-1 Tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures |
| Q34690832 | Loss of neuronal integrity during progressive HIV-1 infection of humanized mice |
| Q30440212 | Lower cognitive reserve in the aging human immunodeficiency virus-infected brain |
| Q34303855 | Macrophages and their relevance in Human Immunodeficiency Virus Type I infection |
| Q37182704 | Macrophages in Progressive Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections |
| Q36365764 | Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. |
| Q90733129 | Manipulation of Mononuclear Phagocytes by HIV: Implications for Early Transmission Events |
| Q92192788 | Mass Spectrometry Imaging Demonstrates the Regional Brain Distribution Patterns of Three First-Line Antiretroviral Drugs |
| Q37313828 | Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems |
| Q28082139 | Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders |
| Q28483960 | Methamphetamine and inflammatory cytokines increase neuronal Na+/K+-ATPase isoform 3: relevance for HIV associated neurocognitive disorders |
| Q34988471 | Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field |
| Q35215604 | Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial |
| Q90264350 | Molecular Imaging of Neuroinflammation in HIV |
| Q37501478 | Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport |
| Q36060674 | Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection |
| Q35979166 | Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells |
| Q35857045 | Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain |
| Q91840250 | Morphine-Induced Modulation of Endolysosomal Iron Mediates Upregulation of Ferritin Heavy Chain in Cortical Neurons |
| Q40058778 | Motor-related brain abnormalities in HIV-infected patients: a multimodal MRI study. |
| Q34343025 | Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. |
| Q34458860 | Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. |
| Q26770401 | Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview |
| Q30391907 | Neural correlates of working memory training in HIV patients: study protocol for a randomized controlled trial |
| Q35872249 | Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation. |
| Q95779068 | Neuroimaging of HIV-associated neurocognitive disorders |
| Q34734802 | Neuroinflammation and virus replication in the spinal cord of simian immunodeficiency virus-infected macaques |
| Q36475300 | Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. |
| Q35751491 | Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa |
| Q41067770 | Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study |
| Q47604267 | Neurological manifestations, laboratory and neuroimaging features in HIV-infected patients |
| Q35220415 | Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine |
| Q37721505 | Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND. |
| Q42268235 | Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain |
| Q35568407 | Neuropsychiatric complications of aging with HIV. |
| Q36845234 | Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection |
| Q92856642 | Neurorestoration of Sustained Attention in a Model of HIV-1 Associated Neurocognitive Disorders |
| Q33870898 | Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport |
| Q36875652 | Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort |
| Q38474693 | New advances on glial activation in health and disease |
| Q91803554 | Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications |
| Q90347974 | Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment |
| Q36739654 | OSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM. |
| Q37624846 | Older individuals with HIV infection have greater memory deficits than younger individuals |
| Q36201412 | Opiate drug use and the pathophysiology of neuroAIDS. |
| Q59360327 | Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy |
| Q37022050 | Oxidative stress and the HIV-infected brain proteome |
| Q47590480 | Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial |
| Q35175447 | Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection |
| Q27011876 | Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment |
| Q36164951 | Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis |
| Q49865980 | Promoter polymorphism MMP-1 (-1607 2G/1G) and MMP-3 (-1612 5A/6A) in development of HAND and modulation of pathogenesis of HAND. |
| Q91728847 | Proteomic analysis of cerebrospinal fluid extracellular vesicles reveals synaptic injury, inflammation, and stress response markers in HIV patients with cognitive impairment |
| Q26827255 | Redefining the viral reservoirs that prevent HIV-1 eradication |
| Q42255469 | Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. |
| Q36941958 | Reproductive health decision-making in perinatally HIV-infected adolescents and young adults |
| Q31135624 | Review of functional MRI in HIV: effects of aging and medication |
| Q61800083 | Role of FOXO3 Activated by HIV-1 Tat in HIV-Associated Neurocognitive Disorder Neuronal Apoptosis |
| Q27025573 | Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders |
| Q36645459 | SAMHD1 transcript upregulation during SIV infection of the central nervous system does not associate with reduced viral load. |
| Q40684397 | SIV Infection Impairs the Central Nervous System in Chinese Rhesus Macaques |
| Q54209057 | SIV Latency in Macrophages in the CNS. |
| Q40570704 | Selective developmental alterations in The HIV-1 transgenic rat: Opportunities for diagnosis of pediatric HIV-1. |
| Q36414630 | Sleep, Fatigue, and Problems With Cognitive Function in Adults Living With HIV. |
| Q28729739 | Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women |
| Q36786375 | Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity? |
| Q36605014 | Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. |
| Q37597459 | Synaptodendritic injury with HIV-Tat protein: What is the therapeutic target? |
| Q34091216 | Tat 101-mediated enhancement of brain pericyte migration involves platelet-derived growth factor subunit B homodimer: implications for human immunodeficiency virus-associated neurocognitive disorders. |
| Q40400564 | Temporal processsing demands in the HIV-1 transgenic rat: Amodal gating and implications for diagnostics. |
| Q54982714 | Temporal/compartmental changes in viral RNA and neuronal injury in a primate model of NeuroAIDS. |
| Q35824975 | The HAND Database: a gateway to understanding the role of HIV in HIV-associated neurocognitive disorders |
| Q45542483 | The Metamorphosis of HIV-Associated Neurocognitive Disorders |
| Q91811038 | The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling |
| Q37522883 | The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis |
| Q40261770 | The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. |
| Q33876868 | The impact of depressive symptoms on patient-provider communication in HIV care |
| Q47127779 | The lipid raft-dwelling protein US9 can be manipulated to target APP compartmentalization, APP processing, and neurodegenerative disease pathogenesis |
| Q42235552 | The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model |
| Q38124430 | The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease |
| Q41922188 | The role of human dopamine transporter in NeuroAIDS. |
| Q34410713 | The role of tau protein in HIV-associated neurocognitive disorders |
| Q91636842 | Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder |
| Q37646891 | Tissue-resident macrophages can contain replication-competent virus in antiretroviral-naive, SIV-infected Asian macaques |
| Q36815240 | Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND |
| Q36429120 | Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women |
| Q37153550 | Tristetraprolin expression and microRNA-mediated regulation during simian immunodeficiency virus infection of the central nervous system |
| Q52567903 | Ultradeep single-molecule real-time sequencing of HIV envelope reveals complete compartmentalization of highly macrophage-tropic R5 proviral variants in brain and CXCR4-using variants in immune and peripheral tissues. |
| Q35264787 | Understanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection |
| Q34652709 | Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals |
| Q47563724 | When do models of NeuroAIDS faithfully imitate "the real thing"? |
Search more.